Association for Molecular Pathology v. Myriad Genetics, Inc.

Myriad Genetics to Participate in Stephens Annual Investment Conference

Retrieved on: 
Thursday, November 9, 2023

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m.

Key Points: 
  • SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m.
  • ET.

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

Retrieved on: 
Wednesday, November 1, 2023

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.

Key Points: 
  • SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.
  • Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in life sciences and molecular diagnostics, to the team at Myriad Genetics.
  • In his role as COO, he will be responsible for driving the company’s lab operations, customer service initiatives, and product development innovations.
  • “Sam is an accomplished leader who understands how to build teams and drive a patient-centric culture, with a proven ability to define, execute and deliver profitable growth for companies within the diagnostics space,” said Paul Diaz, President and CEO, Myriad Genetics.

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

Retrieved on: 
Tuesday, October 31, 2023

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT.

Key Points: 
  • SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT.
  • The company’s quarterly earnings will be released the same day after the market closes.
  • During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2023.
  • An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above.

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

Retrieved on: 
Thursday, September 28, 2023

SALT LAKE CITY, Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.

Key Points: 
  • SALT LAKE CITY, Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9194951-myriad-genetics-cancer-r...
    Women with dense breast tissue are up to four times more likely to develop breast cancer compared to women without dense breasts.1 Higher-density tissue can make it more difficult to detect breast masses or cancer during a screening and may require additional imaging tests.
  • The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024.

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Retrieved on: 
Tuesday, September 19, 2023

“At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, president and chief executive officer, Myriad Genetics.

Key Points: 
  • “At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, president and chief executive officer, Myriad Genetics.
  • At the end of 2022, women made up 62% of the Myriad workforce and 45% of leadership roles.
  • Since 2019, Myriad has recycled approximately 102 tons of plastic from its Salt Lake City laboratories, including 31.4 tons of plastic during 2022.
  • For more information about Myriad’s ESG efforts, read the 2022 report

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Retrieved on: 
Monday, September 18, 2023

SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer.

Key Points: 
  • SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer.
  • Myriad is working together with Pedram Razavi, MD, PhD, a breast medical oncologist and Director of Liquid Biopsy & Genomics at MSK Global Biomarker Development Program.
  • The MSK research team will investigate the use of MRD testing for patients in two breast cancer cohorts.
  • The second will be focused on the neoadjuvant setting and will assess the association of MRD testing with chemotherapy treatment response.

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Retrieved on: 
Tuesday, September 5, 2023

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.

Key Points: 
  • SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.
  • On Sept. 19, Myriad will host an in-person Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco.
  • The Morgan Stanley fireside chat will be available on Myriad’s website at investor.myriad.com .
  • For those unable to attend Myriad’s Investor Day, the presentation and Q&A will also be available at investor.myriad.com .

Myriad Genetics to Host Investor Day on September 19, 2023

Retrieved on: 
Thursday, August 17, 2023

SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco on September 19, 2023.

Key Points: 
  • SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco on September 19, 2023.
  • The Investor Day presentation and Q&A will take place from 10:00 am to 12:00 pm PDT (1:00 pm to 3:00 pm EDT).
  • For those unable to attend in person, a live webcast of the Investor Day presentation and Q&A will be available at www.investor.myriad.com .
  • A replay will be posted on Myriad Genetics’ website after the event and will be available for at least 30 days following.

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Retrieved on: 
Tuesday, August 15, 2023

SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris® Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy. Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT)1.

Key Points: 
  • Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT)1.
  • ADT can be effective at slowing the progression of prostate cancer, but it can also be associated with significant side effects such as bone and muscle loss, weight gain and increased cardiovascular risk.
  • “When men are diagnosed with localized prostate cancer, they have choices about different kinds of therapies.
  • “With the addition of Absolute Risk Reduction to the Prolaris report, patients and their providers can have a more personalized risk-benefit discussion and decide on the most effective treatment path.”
    For more information about Prolaris, visit: https://myriad.com/urology/understanding-the-prolaris-report/

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

Retrieved on: 
Thursday, July 27, 2023

SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m.

Key Points: 
  • SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m.
  • The company’s quarterly earnings will be released the same day after the market closes.
  • During the call, Myriad management will provide a financial overview and business update of the company’s performance for the period ending June 30, 2023.
  • An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above.